Bone Growth Stimulators Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Bone Growth Stimulators Pipeline Market Report Overview

Bone growth stimulators are mainly used to facilitate bone growth in impaired or delayed healing fractures/fusions. Bone growth stimulators apply electrical or ultrasound waves to the site of the fracture/fusion.

The bone growth stimulators pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Segment ·       Implantable Bone Growth Stimulators

·       External Bone Growth Stimulators

Key Territories ·       The United States

·       Europe

·       Canada

·       Australia

·       Brazil

Key Regulatory Paths ·       510(k)

·       CE

·       PMA

·       MDL

·       ANVISA

·       TGA

Leading Companies ·       Collamedix Inc

·       Curative Biosciences, Inc.

·       DJO Global Inc

·       Eepta Pty Ltd

·       Inion Oy

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Buy the Full Report for More Insights into the Bone Growth Stimulators Pipeline Market

Download a Free Report Sample

Bone Growth Stimulators Pipeline Market Segments

The key segments of the bone growth stimulators pipeline market are implantable bone growth stimulators and external bone growth stimulators. As of July 2024, the implantable bone growth stimulators segment accounted for the highest number of pipeline products.

Bone Growth Stimulators Pipeline Market Analysis by Segments, 2024 (%)

Bone Growth Stimulators Pipeline Market Analysis by Segments, 2024 (%)

Buy the Full Report for More Segment Insights into the Bone Growth Stimulators Pipeline Market

Download a Free Report Sample

Bone Growth Stimulators Pipeline Market Segmentation by Territories

The United States (US), Europe, Canada, Australia, and Brazil among others are a few of the key territories of the bone growth stimulators pipeline market. As of July 2024, the US accounted for the highest number of pipeline products.

Bone Growth Stimulators Pipeline Market Analysis by Territories, 2024 (%)

Bone Growth Stimulators Pipeline Market Analysis by Territories, 2024 (%)

Buy the Full Report for More Territory Insights into the Bone Growth Stimulators Pipeline Market

Download a Free Report Sample

Bone Growth Stimulators Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths in the bone growth stimulators pipeline products market are 510(k), CE, PMA, MDL, ANVISA, and TGA. As of July 2024, 510(k) was the most followed pathway for pipeline products in the bone growth stimulators market.

Bone Growth Stimulators Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Bone Growth Stimulators Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Buy the Full Report for More Regulatory Path Insights into the Bone Growth Stimulators Pipeline Market

Download a Free Report Sample

Bone Growth Stimulators Pipeline Market – Competitive Landscape

A few of the key companies associated with the bone growth stimulators pipeline market are Collamedix Inc., Curative Biosciences, Inc., DJO Global Inc., Eepta Pty Ltd, and Inion Oy among others.

DJO Global Inc: DJO Global Inc (DJO), a subsidiary of Enovis Corp, is a medical device company. It manufactures and distributes medical devices for musculoskeletal health, joint reconstruction, vascular health, and pain management. The company’s products include rigid and soft orthopedic bracing, bone growth stimulators, hot and cold therapy, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators for pain management, and physical therapy products.

Bone Growth Stimulators Pipeline Market Analysis by Companies, 2024
Bone Growth Stimulators Pipeline Market Analysis by Companies, 2024
Buy the Full Report for More Company Insights into the Bone Growth Stimulators Pipeline Market
Download a Free Report Sample

Segments Covered in the Report

Bone Growth Stimulators Pipeline Market Segments Outlook (2024)

  • Implantable Bone Growth Stimulators
  • External Bone Growth Stimulators

Bone Growth Stimulators Pipeline Market Territories Outlook (2024)

  • The United States
  • Europe
  • Canada
  • Australia
  • Brazil

Bone Growth Stimulators Pipeline Market Regulatory Paths Outlook (2024)

  • 510(k)
  • CE
  • PMA
  • MDL
  • ANVISA
  • TGA

Scope

This report provides:

  • Extensive coverage of the bone growth stimulators under development.
  • Exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.
  • Reviews of major players involved in developing bone growth stimulators and lists all their pipeline projects.
  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
  • Key clinical trial data of ongoing clinical trials specific to pipeline products.
  • Recent developments in the segment/industry.

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.
  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
  • Identify and understand important and diverse types of bone growth stimulators under development.
  • Develop market-entry and market-expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • Carry out an in-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Bionext Biotech Products Ltd.
Center for Biomedical Research Network in Bioengineering, Biomaterials and Nanomedicine
Collamedix Inc
Curative Biosciences, Inc.
DJO Global Inc
Eepta Pty Ltd
GreenBone Ortho srl
Industrie Biomediche Insubri SA
Inion Oy
Johns Hopkins University
KeraCure, Inc. (Inactive)
Lattice Biologics Ltd
Magle Chemoswed AB
Max Biopharma Inc
NC Biomatrix BV
NDSU Research Foundation
Oklahoma State University
Oligo Medic Inc
Orthocell Ltd
Orthofix Medical Inc
OsteoGenix Incorporated (Inactive)
REGENECURE Ltd
Texas A&M University
The University of Nottingham
Universiti Putra Malaysia
University of California Davis
University of Florida
University of Wisconsin Madison
Wright Medical Group NV (Inactive)
ZetaGen Therapeutics Inc

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 6

|1.2 List of Figures 9

2 Introduction 10

2.1 Bone Growth Stimulators Overview 10

3 Products under Development 11

3.1 Bone Growth Stimulators – Pipeline Products by Stage of Development 11

3.2 Bone Growth Stimulators – Pipeline Products by Segment 12

3.3 Bone Growth Stimulators – Pipeline Products by Territory 13

3.4 Bone Growth Stimulators – Pipeline Products by Regulatory Path 14

3.5 Bone Growth Stimulators – Pipeline Products by Estimated Approval Date 15

3.6 Bone Growth Stimulators – Ongoing Clinical Trials 16

4 Bone Growth Stimulators – Pipeline Products under Development by Companies 17

4.1 Bone Growth Stimulators Companies – Pipeline Products by Stage of Development 17

4.2 Bone Growth Stimulators – Pipeline Products by Stage of Development 19

5 Bone Growth Stimulators Companies and Product Overview 20

5.1 Bionext Biotech Products Ltd. Company Overview 20

5.1.1 Bionext Biotech Products Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20

5.2 Center for Biomedical Research Network in Bioengineering, Biomaterials and Nanomedicine Company Overview 21

5.2.1 Center for Biomedical Research Network in Bioengineering, Biomaterials and Nanomedicine Pipeline Products & Ongoing Clinical Trials Overview 21

5.3 Collamedix Inc Company Overview 22

5.3.1 Collamedix Inc Pipeline Products & Ongoing Clinical Trials Overview 22

5.4 Curative Biosciences, Inc. Company Overview 23

5.4.1 Curative Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23

5.5 DJO Global Inc Company Overview 25

5.5.1 DJO Global Inc Pipeline Products & Ongoing Clinical Trials Overview 25

5.6 Eepta Pty Ltd Company Overview 26

5.6.1 Eepta Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

5.7 GreenBone Ortho srl Company Overview 27

5.7.1 GreenBone Ortho srl Pipeline Products & Ongoing Clinical Trials Overview 27

5.8 Industrie Biomediche Insubri SA Company Overview 30

5.8.1 Industrie Biomediche Insubri SA Pipeline Products & Ongoing Clinical Trials Overview 30

5.9 Inion Oy Company Overview 31

5.9.1 Inion Oy Pipeline Products & Ongoing Clinical Trials Overview 31

5.10 Johns Hopkins University Company Overview 32

5.10.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 32

5.11 KeraCure, Inc. (Inactive) Company Overview 33

5.11.1 KeraCure, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

5.12 Lattice Biologics Ltd Company Overview 34

5.12.1 Lattice Biologics Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

5.13 Magle Chemoswed AB Company Overview 35

5.13.1 Magle Chemoswed AB Pipeline Products & Ongoing Clinical Trials Overview 35

5.14 Max Biopharma Inc Company Overview 36

5.14.1 Max Biopharma Inc Pipeline Products & Ongoing Clinical Trials Overview 36

5.15 NC Biomatrix BV Company Overview 37

5.15.1 NC Biomatrix BV Pipeline Products & Ongoing Clinical Trials Overview 37

5.16 NDSU Research Foundation Company Overview 38

5.16.1 NDSU Research Foundation Pipeline Products & Ongoing Clinical Trials Overview 38

5.17 Oklahoma State University Company Overview 39

5.17.1 Oklahoma State University Pipeline Products & Ongoing Clinical Trials Overview 39

5.18 Oligo Medic Inc Company Overview 40

5.18.1 Oligo Medic Inc Pipeline Products & Ongoing Clinical Trials Overview 40

5.19 Orthocell Ltd Company Overview 41

5.19.1 Orthocell Ltd Pipeline Products & Ongoing Clinical Trials Overview 41

5.20 Orthofix Medical Inc Company Overview 42

5.20.1 Orthofix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 42

5.21 OsteoGenix Incorporated (Inactive) Company Overview 45

5.21.1 OsteoGenix Incorporated (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 45

5.22 REGENECURE Ltd Company Overview 46

5.22.1 REGENECURE Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

5.23 Texas A&M University Company Overview 47

5.23.1 Texas A&M University Pipeline Products & Ongoing Clinical Trials Overview 47

5.24 The University of Nottingham Company Overview 48

5.24.1 The University of Nottingham Pipeline Products & Ongoing Clinical Trials Overview 48

5.25 Universiti Putra Malaysia Company Overview 49

5.25.1 Universiti Putra Malaysia Pipeline Products & Ongoing Clinical Trials Overview 49

5.26 University of California Davis Company Overview 50

5.26.1 University of California Davis Pipeline Products & Ongoing Clinical Trials Overview 50

5.27 University of Florida Company Overview 51

5.27.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 51

5.28 University of Wisconsin Madison Company Overview 52

5.28.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 52

5.29 Wright Medical Group NV (Inactive) Company Overview 53

5.29.1 Wright Medical Group NV (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 53

5.30 ZetaGen Therapeutics Inc Company Overview 54

5.30.1 ZetaGen Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 54

6 Bone Growth Stimulators- Recent Developments 58

6.1 Jul 01, 2024: Stryker to Announce Financial Results for its Second Quarter of Fiscal Year 2024 58

6.2 Jun 26, 2024: Medtronic Announces Departure of Karen Parkhill, Chief Financial Officer 58

6.3 Jun 26, 2024: Medtronic CFO Transition and Interim Appointment Update 58

6.4 Jun 18, 2024: Aviva McPherron Joins Orthofix as President of Global Operations and Quality 58

6.5 Jun 17, 2024: Medtronic EVP, Global Regions President Rob ten Hoedt is Retiring 59

6.6 Jun 13, 2024: Medtronic Confirms Global Layoffs 59

6.7 Jun 04, 2024: Medtronic Announces Dr. Goran Petrovski to Join Diabetes Medical Affairs Team 59

6.8 Jun 04, 2024: Medtronic Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024 59

6.9 May 07, 2024: Globus Medical Reports First Quarter 2024 Results 59

6.10 May 02, 2024: Zimmer Biomet Announces First Quarter 2024 Financial Results 60

6.11 Apr 24, 2024: Medtronic Names Yarmela Pavlovic as Chief Regulatory Officer 61

6.12 Apr 16, 2024: Xstim Receives FDA Approval for Xstim Spine Fusion Stimulator 61

6.13 Mar 13, 2024: Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023 62

6.14 Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference 63

6.15 Feb 27, 2024: Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024 63

6.16 Feb 19, 2024: Xstim Obtains Pre-Market Approval (PMA) for Spine Fusion Stimulator 64

6.17 Feb 15, 2024: Integer Holdings Reports Results for Fourth Quarter and Full Year 2023 64

6.18 Jan 31, 2024: Stryker Corp Reports Strong Q4 and Full Year 2023 Results; Forecasts Continued Growth 66

6.19 Jan 10, 2024: Integer Holdings Announces Preliminary Unaudited Sales Results and Acquisition of Pulse Technologies 66

6.20 Dec 21, 2023: Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis 68

6.21 Oct 26, 2023: Integer Holdings Reports Third Quarter 2023 Results 69

6.22 Oct 10, 2023: Zetagen Announces Publication in Pain Management of Early Data Using ZetaMet as a Potential Treatment for Bone Metastases 70

6.23 Oct 10, 2023: Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023 71

6.24 Oct 09, 2023: Stryker to Host Investor Day 71

6.25 Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business 72

6.26 Oct 02, 2023: Stryker to Announce Financial Results for Its Third Quarter of Fiscal Year 2023 72

6.27 Sep 28, 2023: Integer Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 72

6.28 Sep 05, 2023: Zimmer Biomet Announces Key Updates to Company’s Executive Leadership Team 73

6.29 Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair 74

6.30 Aug 24, 2023: CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million 74

6.31 Aug 22, 2023: Zimmer Biomet Announces Leadership Transition 77

6.32 Aug 09, 2023: Collplant Biotechnologies Announces Date for 2023 Second Quarter Financial Results and Conference Call Information 78

6.33 Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024 79

7 Appendix 80

7.1 Methodology 80

7.2 About GlobalData 83

7.3 Contact Us 83

7.4 Disclaimer 83

Table

Bone Growth Stimulators – Pipeline Products by Stage of Development 11

Bone Growth Stimulators – Pipeline Products by Segment 12

Bone Growth Stimulators – Pipeline Products by Territory 13

Bone Growth Stimulators – Pipeline Products by Regulatory Path 14

Bone Growth Stimulators – Pipeline Products by Estimated Approval Date 15

Bone Growth Stimulators – Ongoing Clinical Trials 16

Bone Growth Stimulators Companies – Pipeline Products by Stage of Development 17

Bone Growth Stimulators – Pipeline Products by Stage of Development 19

Bionext Biotech Products Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20

Orthonext – Product Status 20

Orthonext – Product Description 20

Center for Biomedical Research Network in Bioengineering, Biomaterials and Nanomedicine Pipeline Products & Ongoing Clinical Trials Overview 21

Bioactive Glass Scaffold – Product Status 21

Bioactive Glass Scaffold – Product Description 21

Collamedix Inc Pipeline Products & Ongoing Clinical Trials Overview 22

AlloBrace – Product Status 22

AlloBrace – Product Description 22

Curative Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23

Nurture BSP – Product Status 23

Nurture BSP – Product Description 23

Osteoconductive Scaffold – Product Status 24

Osteoconductive Scaffold – Product Description 24

DJO Global Inc Pipeline Products & Ongoing Clinical Trials Overview 25

CMF OL1000 – Fresh Ankle Fracture – Product Status 25

CMF OL1000 – Fresh Ankle Fracture – Product Description 25

Eepta Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

Bone Growth Scaffold – Product Status 26

Bone Growth Scaffold – Product Description 26

GreenBone Ortho srl Pipeline Products & Ongoing Clinical Trials Overview 27

b.Bone Implant – Product Status 27

b.Bone Implant – Product Description 27

GreenBone Ortho srl – Ongoing Clinical Trials Overview 28

b.Bone Implant – A Post-market Clinical Follow-up Investigation to Confirm the Performance and Safety of the Bone Substitute b.Bone in Extremities and Pelvis 29

b.Bone Implant – A Pre-market, Open-label, Single-arm Study to Evaluate b.Bone for Posterolateral Fusion Treatment of Degenerative Thoracolumbar, Lumbar or Lumbosacral Spinal Disease (b.Spine Clinical Trial). 29

Industrie Biomediche Insubri SA Pipeline Products & Ongoing Clinical Trials Overview 30

SmartPepPutty – Product Status 30

SmartPepPutty – Product Description 30

Inion Oy Pipeline Products & Ongoing Clinical Trials Overview 31

Inion Optimaplus – Product Status 31

Inion Optimaplus – Product Description 31

Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 32

3D-printed Bone Extracellular Matrix Scaffold – Product Status 32

3D-printed Bone Extracellular Matrix Scaffold – Product Description 32

KeraCure, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

KeraPac – Bone Regeneration – Product Status 33

KeraPac – Bone Regeneration – Product Description 33

Lattice Biologics Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

Bone Scaffold + ECM – Product Status 34

Bone Scaffold + ECM – Product Description 34

Magle Chemoswed AB Pipeline Products & Ongoing Clinical Trials Overview 35

SmartBone – Product Status 35

SmartBone – Product Description 35

Max Biopharma Inc Pipeline Products & Ongoing Clinical Trials Overview 36

Oxy133 Implantable Device – Product Status 36

Oxy133 Implantable Device – Product Description 36

NC Biomatrix BV Pipeline Products & Ongoing Clinical Trials Overview 37

Vitadisc – Product Status 37

Vitadisc – Product Description 37

NDSU Research Foundation Pipeline Products & Ongoing Clinical Trials Overview 38

Bone Scaffold – Product Status 38

Bone Scaffold – Product Description 38

Oklahoma State University Pipeline Products & Ongoing Clinical Trials Overview 39

Bone Repair Scaffold – Product Status 39

Bone Repair Scaffold – Product Description 39

Oligo Medic Inc Pipeline Products & Ongoing Clinical Trials Overview 40

BoneRep – Product Status 40

BoneRep – Product Description 40

Orthocell Ltd Pipeline Products & Ongoing Clinical Trials Overview 41

CelGro SMRT Graft – Bone Repair – Product Status 41

CelGro SMRT Graft – Bone Repair – Product Description 41

Orthofix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 42

Cervical-Stim Osteogenesis Stimulator – Odontoid Fractures – Product Status 42

Cervical-Stim Osteogenesis Stimulator – Odontoid Fractures – Product Description 42

Physio-Stim Osteogenesis Stimulator – Osteoarthritis – Product Status 43

Physio-Stim Osteogenesis Stimulator – Osteoarthritis – Product Description 43

RCStim Device – Product Status 43

RCStim Device – Product Description 44

OsteoGenix Incorporated (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 45

Bone Anabolic Agent – Product Status 45

Bone Anabolic Agent – Product Description 45

REGENECURE Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

Regenecure AMCA GBR Bone Membrane Implant – Product Status 46

Regenecure AMCA GBR Bone Membrane Implant – Product Description 46

Texas A&M University Pipeline Products & Ongoing Clinical Trials Overview 47

Bioactive Foam Based Moldable Scaffold – Product Status 47

Bioactive Foam Based Moldable Scaffold – Product Description 47

The University of Nottingham Pipeline Products & Ongoing Clinical Trials Overview 48

Injectable Bone – Product Status 48

Injectable Bone – Product Description 48

Universiti Putra Malaysia Pipeline Products & Ongoing Clinical Trials Overview 49

Nanocomposite Bone Scaffold – Product Status 49

Nanocomposite Bone Scaffold – Product Description 49

University of California Davis Pipeline Products & Ongoing Clinical Trials Overview 50

Synthetic Bone Matrix – Product Status 50

Synthetic Bone Matrix – Product Description 50

University of Florida Pipeline Products & Ongoing Clinical Trials Overview 51

Bone Tissue Scaffold – Product Status 51

Bone Tissue Scaffold – Product Description 51

University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 52

Fracture Electrostimulation Device – Product Status 52

Fracture Electrostimulation Device – Product Description 52

Wright Medical Group NV (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 53

Soft Tissue Graft – Product Status 53

Soft Tissue Graft – Product Description 53

ZetaGen Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 54

Nalovent Bone Graft – Product Status 54

Nalovent Bone Graft – Product Description 54

ZetaMet – Product Status 55

ZetaMet – Product Description 55

ZetaGen Therapeutics Inc – Ongoing Clinical Trials Overview 56

ZetaMet – Ten Patient Pilot Study to Evaluate Safety of the ZetaFuse™ Bone Graft Administered Using an Outpatient Local Intratumoral Injection Procedure to Treat Breast Cancer Bone Metastases in the Spine to Control Pain and Prevent Complications Such as Fracture 57

Glossary 82

Figures

Bone Growth Stimulators – Pipeline Products by Stage of Development 11

Bone Growth Stimulators – Pipeline Products by Segment 12

Bone Growth Stimulators – Pipeline Products by Territory 13

Bone Growth Stimulators – Pipeline Products by Regulatory Path 14

Bone Growth Stimulators – Pipeline Products by Estimated Approval Date 15

Bone Growth Stimulators – Ongoing Clinical Trials 16

Frequently asked questions

Bone Growth Stimulators Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies standard reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Bone Growth Stimulators Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bone Growth Stimulators Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies in real time.

  • Access a live Bone Growth Stimulators Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.